1. Scrip
  2. >>COVID-19

Coronavirus Update: Moderna Prepares For Crucial Phase II Trial Of Vaccine, Japan Takes Steps

At Risk Age Groups Added To Phase I Studies

 
• By Scrip Team

Plus: Japan pledges rapid approval for remdesivir, GSK launches fund to look into impact of coronavirus on people with HIV.  

Tokyo
Asakusa, Tokyo, Japan. Japan has a relatively small number of COVID-19 cases and deaths compared to other countries, but a recent surge in cases in Tokyo has led to stricter measures being introduced. At the start of the Golden Week holiday, the government is asking citizens to stay at home for the entire period.

Moderna Inc. is looking to move its coronavirus vaccine candidate mRNA-1273 rapidly into Phase II trials.

The company has become one of the frontrunners in the race to develop a vaccine, despite its mRNA-based platform being relatively unproven, and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.